Reshaping Our Knowledge: Advancements in Understanding the Immune Response to Human Respiratory Syncytial Virus

Overview

Journal Pathogens

Date 2023 Sep 28

PMID 37764926

Authors

Federica Attaianese

Sara Guiducci

Sandra Trapani

Federica Barbati

Lorenzo Lodi

Giuseppe Indolfi

Chiara Azzari

Silvia Ricci

Affiliations

Soon will be listed here.

Abstract

Human respiratory syncytial virus (hRSV) is a significant cause of respiratory tract infections, particularly in young children and older adults. In this review, we aimed to comprehensively summarize what is known about the immune response to hRSV infection. We described the innate and adaptive immune components involved, including the recognition of RSV, the inflammatory response, the role of natural killer (NK) cells, antigen presentation, T cell response, and antibody production. Understanding the complex immune response to hRSV infection is crucial for developing effective interventions against this significant respiratory pathogen. Further investigations into the immune memory generated by hRSV infection and the development of strategies to enhance immune responses may hold promise for the prevention and management of hRSV-associated diseases.

Citing Articles

Trend of pathogens and respiratory co-infections in the province of Messina: from pediatric age to senescence.

Genovese C, Gorgone M, Genovese G, La Spada G, Balsamo D, Calderone S J Prev Med Hyg. 2025; 65(3):E344-E355.

PMID: 39758766 PMC: 11698104. DOI: 10.15167/2421-4248/jpmh2024.65.3.3344.

Immune Responses to Respiratory Syncytial Virus Vaccines: Advances and Challenges.

Silva G, Borges S, Pozzebon B, Souza A Microorganisms. 2024; 12(11).

PMID: 39597694 PMC: 11596275. DOI: 10.3390/microorganisms12112305.

The Role of the CX3CR1-CX3CL1 Axis in Respiratory Syncytial Virus Infection and the Triggered Immune Response.

Rivas-Fuentes S, Salgado-Aguayo A, Santos-Mendoza T, Sevilla-Reyes E Int J Mol Sci. 2024; 25(18).

PMID: 39337288 PMC: 11432029. DOI: 10.3390/ijms25189800.

A Mixture of T-Cell Epitope Peptides Derived from Human Respiratory Syncytial Virus F Protein Conferred Protection in DR1-TCR Tg Mice.

Guo H, Song Y, Li H, Hu H, Shi Y, Jiang J Vaccines (Basel). 2024; 12(1).

PMID: 38250890 PMC: 10820450. DOI: 10.3390/vaccines12010077.

References

Chirkova T, Lin S, Oomens A, Gaston K, Boyoglu-Barnum S, Meng J . CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol. 2015; 96(9):2543-2556. PMC: 4635495. DOI: 10.1099/vir.0.000218. View

Kuhdari P, Brosio F, Malaventura C, Stefanati A, Orsi A, Icardi G . Human respiratory syncytial virus and hospitalization in young children in Italy. Ital J Pediatr. 2018; 44(1):50. PMC: 5935991. DOI: 10.1186/s13052-018-0492-y. View

Sakaguchi S, Yamaguchi T, Nomura T, Ono M . Regulatory T cells and immune tolerance. Cell. 2008; 133(5):775-87. DOI: 10.1016/j.cell.2008.05.009. View

Bermingham A, Collins P . The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A. 1999; 96(20):11259-64. PMC: 18021. DOI: 10.1073/pnas.96.20.11259. View

Kim H, Lee M, Lee J . Eosinophil cationic protein and chemokines in nasopharyngeal secretions of infants with respiratory syncytial virus (RSV) bronchiolitis and non-RSV bronchiolitis. J Korean Med Sci. 2007; 22(1):37-42. PMC: 2693566. DOI: 10.3346/jkms.2007.22.1.37. View

Verwey C, Madhi S . Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus. BioDrugs. 2023; 37(3):295-309. PMC: 10127166. DOI: 10.1007/s40259-023-00596-4. View

Freihorst J, Ogra P . Mucosal immunity and viral infections. Ann Med. 2001; 33(3):172-7. DOI: 10.3109/07853890109002074. View

Johnson S, McNally B, Ioannidis I, Flano E, Teng M, Oomens A . Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog. 2015; 11(12):e1005318. PMC: 4676609. DOI: 10.1371/journal.ppat.1005318. View

Munir S, Le Nouen C, Luongo C, Buchholz U, Collins P, Bukreyev A . Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol. 2008; 82(17):8780-96. PMC: 2519638. DOI: 10.1128/JVI.00630-08. View

10.

Mart Nez I, Vald S O, Delfraro A, Arbiza J, Russi J, Melero J . Evolutionary pattern of the G glycoprotein of human respiratory syncytial viruses from antigenic group B: the use of alternative termination codons and lineage diversification. J Gen Virol. 1999; 80 ( Pt 1):125-130. DOI: 10.1099/0022-1317-80-1-125. View

11.

Shah J, Chemaly R . Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2010; 117(10):2755-63. DOI: 10.1182/blood-2010-08-263400. View

12.

Antunes K, Becker A, Franceschina C, de Freitas D, Lape I, da Cunha M . Respiratory syncytial virus reduces STAT3 phosphorylation in human memory CD8 T cells stimulated with IL-21. Sci Rep. 2019; 9(1):17766. PMC: 6882881. DOI: 10.1038/s41598-019-54240-9. View

13.

Moyes J, Cohen C, Pretorius M, Groome M, von Gottberg A, Wolter N . Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011. J Infect Dis. 2013; 208 Suppl 3:S217-26. DOI: 10.1093/infdis/jit479. View

14.

Garegnani L, Styrmisdottir L, Roson Rodriguez P, Escobar Liquitay C, Esteban I, Franco J . Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021; 11:CD013757. PMC: 8594174. DOI: 10.1002/14651858.CD013757.pub2. View

15.

Den Hartog G, van Kasteren P, Schepp R, Teirlinck A, van der Klis F, Van Binnendijk R . Decline of RSV-specific antibodies during the COVID-19 pandemic. Lancet Infect Dis. 2022; 23(1):23-25. PMC: 9714975. DOI: 10.1016/S1473-3099(22)00763-0. View

16.

Feng Z, Xu L, Xie Z . Receptors for Respiratory Syncytial Virus Infection and Host Factors Regulating the Life Cycle of Respiratory Syncytial Virus. Front Cell Infect Microbiol. 2022; 12:858629. PMC: 8913501. DOI: 10.3389/fcimb.2022.858629. View

17.

Dee K, Schultz V, Haney J, Bissett L, Magill C, Murcia P . Influenza A and Respiratory Syncytial Virus Trigger a Cellular Response That Blocks Severe Acute Respiratory Syndrome Virus 2 Infection in the Respiratory Tract. J Infect Dis. 2022; 227(12):1396-1406. PMC: 10266949. DOI: 10.1093/infdis/jiac494. View

18.

Bukreyev A, Yang L, Fricke J, Cheng L, Ward J, Murphy B . The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol. 2008; 82(24):12191-204. PMC: 2593351. DOI: 10.1128/JVI.01604-08. View

19.

Wang Y, Zheng J, Wang X, Yang P, Zhao D . Alveolar macrophages and airway hyperresponsiveness associated with respiratory syncytial virus infection. Front Immunol. 2022; 13:1012048. PMC: 9630648. DOI: 10.3389/fimmu.2022.1012048. View

20.

Li Y, Wang X, Blau D, Caballero M, Feikin D, Gill C . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399(10340):2047-2064. PMC: 7613574. DOI: 10.1016/S0140-6736(22)00478-0. View